Allogeneic hematopoietic stem cell transplantation for 16 patients with aplastic anemia.
- Author:
Wei-Hua ZHAI
1
;
Mei WANG
;
Zheng ZHOU
;
Wen-Jing ZHAI
;
Rong-Li ZHANG
;
Hua WANG
;
A-Xia SONG
;
Si-Zhou FENG
;
Ming-Zhe HAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Anemia, Aplastic; therapy; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; prevention & control; Graft vs Host Disease; prevention & control; Hematopoietic Stem Cell Transplantation; methods; Humans; Male; Middle Aged; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2007;28(2):78-82
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA).
METHODSTwelve patients with severe AA (SAA) and 4 with chronic AA (CAA) received allo- HSCT. The effectiveness and complication were analyzed retrospectively.
RESULTSHematopoiesis reconstitution was achieved 14 patients (87.50%). The median time of neutrophils reached to 0.5 x 10(9)/L and platelets reached to 20 x 10(9)/L were 14 (11 - 16) and 14 (10 - 33) days, respectively. Six cases developed grade I - II acute graft-versus-host disease (aGVHD), chronic local GVHD occurred in 2 patients. Graft rejection occurred in 3 cases. Thirteen cases survived with a median of 10 (0.5 - 84) months at the end of follow-up. Three cases died of un-engraftment, graft rejection (GR) and interstitial pneumonia (IP) each.
CONCLUSIONAllo-HSCT is an effective therapy for patients with AA. Enhancing immunosuppressive treatment for conditioning and GVHD prophylaxis may reduce the incidence of GR and GVHD.
